Important molecular features, such as isocitrate dehydrogenases (IDH) mutations, which require testing for the workup of all gliomas, and O-6-Methylguanine-DNA methyltransferase (MGMT) promoter methylation are important clinical markers in adult-type infiltrating tumors, affecting patient outcomes [6,7,8,9,10]. This evidence concerns the gene MGMT and central nervous system cancer.